NEXT GENERATION HAIR GROWTH THERAPIES

Corporate PresentationMarch 2020

This presentation contains forward-looking statements that reflect the Company’s current expectationsregarding future events. There’s a risk that expectations, and the forward-looking statements on which theyare based, will not prove to be accurate.

Readers are cautioned not to place undue reliance on forward-looking statements, as they involve risks and uncertainties that couldmake actual results differ materially from those projected therein and depend on a number of factors, including, but not limited to, theCompany’s lack of history of profitability, the availability of future financing, the Company’s ability to protect its intellectual propertyrights and obtain patents, dependence on key personnel, the competitiveness of the marketplace, technological obsolescence, and otherrisks described from time to time in the Company’s documents.

While Triple Hair acknowledges that future events and developments may cause its views to change, it undertakes no obligation toupdate forward-looking statements, except as required by applicable securities laws.

FORWARD-LOOKING STATEMENTS

2

HISTORY

Dr. Sekhavat was balding and tried several known treatments,

which led to disappointing results. Through his medical

background, he decided to start his own research by

combining known molecules to achieve better efficacy.

He shared his theories with Peter and Donna, who provided

him with their expertise and tools he needed for his research,

which led to the creation of Triple Hair.

After many years of research and trials, Triple Hair has

succeeded in creating effective products to stimulate hair

growth, namely its TH07 prescription drug that will undergo

FDA Phase 3 clinical trials.

3

Triple Hair was founded in 2012 by

Dr. Houfar Sekhavat, Dr. Peter Ford and Ms. Donna Steeves,

self-made New Brunswick

entrepreneurs.

3

OVERVIEW

• Triple Hair is developing the next generation topical hair growth therapies

that will disrupt the US$8.5 billion global hair loss market.

• Triple Hair is the only company to develop effective topical products for both

the prescription drug market (TH07) and the over-the-counter (OTC) market

(TH16 and TH18):

- TH07 is a 3-in-1 prescription drug based on effective and approved known

active ingredients.

- TH16 is a natural product based on known natural active ingredients.

- TH18 is a newly created non-prescription drug.

• Triple Hair is already well financed with over $1.8 million in cash and access to a

$369,000 loan from ACOA.

44

MANAGEMENT TEAM

Jean-Philippe Gravel, MBA

President and CEO• Over 15 years of experience in management

and business development mainly with medical, pharmaceutical and natural health product companies: CEO of TSXV-listed Mondias Natural Products; VP, Business Development at Capilia, a North American leader in hair loss solutions.

Erika Tremblay-Gagnon, CPA CA, M.Sc.

Chief Financial Officer• Over 14 years of financial executive experience,

mainly as VP, Corporate Finance with TSX-listed Stingray Group ($400 million market cap) and Senior Manager, Audit and Certification at PricewaterhouseCoopers.

CONSULTANTS

API Sourcing

Formulation / CMO Identification

Regulatory – Pathway Study Design

Clinical Manager

CRO Consultant

Tax Credits, Grants and Funding

5

Satish Asotra, Ph.D., MBA

Chief Scientific Officer• Senior executive and strategic leader with a proven

track record of driving pharmaceutical development, innovation and process improvement with 25 years of experience, including more than 12 years in topical and dermatological product development, with Avicanna, AHI, Accucaps, Odan Laboratories and Taro Pharmaceuticals.

Attila Hajdu, M.Sc., MBA

Vice President, Business Development• Accomplished leader with over 20 years of

experience years in the global pharmaceutical and biotechnology industry, mainly in business development, sales, marketing, finance and medical affairs with XCO Tech, Stelvia Therapeutics, Sirona Biochem, GlaxoSmithKline and Astellas Pharma.

MARKET DYNAMICS

68% of the hair loss market consists of topical and oral

therapies, including Rogaine and Propecia.

Minoxidil (Rogaine) and Finasteride (Propecia) are the only 2 FDA

approved drugs in the hair loss market for the past 20+ years.

Rogaine and the private label Minoxidil versions control

98% of the topical hair growth market in the U.S., with sales

of close to $870 million (2017).

In Canada, the hair growth product industry is

estimated at $170 million.

Patents have expired for Rogaine and Propecia, allowing Triple

Hair to efficiently compete in this large market.

Hair growth products are lifetime-use products: clients on average

will easily spend $5,000 per year over a 20-year period.

6

HAIR LOSS MARKET

GLOBAL:US$8.5 billion (2018)

NORTH AMERICA:US$3.9 billion (2018)

GLOBAL PROJECTED:US$12.4 billion (2025)

Source: Grand ViewResearch 2019

TODAY’S HAIR LOSS MARKET IMAGE

”American hair loss sufferers spend more than 3.5 billion dollars a year in

an attempt to treat their hair loss. Unfortunately, 99% of all products

being marketed in the less than ethical hair loss treatment industry are

completely ineffective for the majority of those who use them.”

-

The Washington Post

“This market segment includes everything from snake oil remedies

where an estimated 99% of products are of a dubious nature. The best

the industry has to offer is Minoxidil (Rogaine).”

-

Biotech and healthcare analyst

7

Rogaine (Minoxidil)

• Over-the-counter liquid or foam to rub onto the scalp twice a day.• May be used by men (5%) and women (3%).• Effect peaks at 16 weeks and patients need to keep applying the medication to

retain benefits.

Propecia (Finasteride)

• Prescription drug indicated only for men.• Taken daily in pill form.• Many men taking finasteride experience a slowing of hair loss, and some may

show some new hair growth.• Common side effects include headache, swelling and nausea.• Serious side effects include depression, gynecomastia, impotence, erectile

dysfunction, male breast cancer and prostate cancer.

8

COMPETITION – MAIN BRANDS

TH07PRESCRIPTION

DRUG

9

Completed Phase 2 Study

• 6-month randomized, double-blind and comparative study

involving 40 men between the ages of 24 and 65.

Results

• Study has shown superior efficacy and safety vs Finasteride

(oral) and Minoxidil (topical gold standard), with single daily

topical dosage.

• Based on these outstanding results, the FDA has given a

roadmap for Triple Hair to start a Phase 3 under 505(2)(b).

Hypothesis

• The combination of three existing and approved drugs will

create a synergistic efficiency for hair regrowth as compared

to its components used as monotherapies.

10

TH07 HYPOTHESIS AND RESULTS TO DATE

TH07 RESULTS

Regrowth Levels

Treatment Regrowth Dense Moderate Minimal None

Triple Hair (TH07) 100% 52% 30% 17% 0%

Propecia(Finasteride) 50% 0% 25% 25% 50%

Rogaine(Minoxidil) 25% 0% 0% 25% 75%

TH07 RESULTS 6-month treatment – Founder Houfar Sekhavat

BEFORE

11

AFTER

TH07 RESULTS 6-month treatment – Patient RL

12

BEFORE AFTER

6-month treatment – Patient GW

13

TH07 RESULTS

BEFORE AFTER

2020 ------------------------------------------------• Secure sourcing of active ingredients

• Stability testing

• Pharmacokinetics testing

• Possible Pre-Phase 3 clinical trial to accelerate process and

reduce costs

2021 ------------------------------------------------• Phase 3 clinical trial

• Identify possible pharma partner to develop and market TH07

• Commercialization plan

14

TH07 Product Development Strategy

TH16NATURALPRODUCT

15

TH16 HYPOTHESIS AND RESULTS TO DATE

Study Process

• 6-month randomized, double-blind and

comparative study involving 33 patients

between the ages of 24 and 65.

Hypothesis

• The combination of two existing and approved

natural health products will create a synergistic

efficiency for hair regrowth as compared to its

components used as monotherapies.

Results

• Study has shown superior efficacy than

monotherapies and Minoxidil 5% (topical

gold standard).

16

Product A Product B

• Non-irritating solution with no serious side effects or drug interactions.

• Can be used safely in combination with existing hair growth products such

as Rogaine (Minoxidil) to improve results.

• Superior at stopping hair loss and increasing the number, thickness and

pigmentation of hair.

• Conveniently applied once daily (Minoxidil products require twice daily

application).

• Safe for use by both women and men (Minoxidil 5% cannot be used by

women).

17

TH16 Other Key Advantages

6-month treatment – Patient GB

18

TH16 RESULTS

BEFORE AFTER

3-month treatment – Patient SB

19

TH16 RESULTS

BEFORE AFTER

3-month treatment – Patient ME

20

TH16 RESULTS

BEFORE AFTER

2020 ------------------------------------------------

• Complete market analysis

• Direct to consumer - launch TH16 via online e-commerce platform

2021 ------------------------------------------------• Retail distribution

• Private label market – International distributors

21

TH16 Product Development Strategy

TH18NON-PRESCRIPTION

DRUG

Product / Study / Results

• Blend of TH16 and Minoxidil 5%.

• Study done on a small group of patients for information

gathering purposes.

• Preliminary results to date show even better results

than by using TH16 alone.

Next Steps

• Further studies to better evaluate efficacy and safety.

• File for Health Canada and FDA Drug Identification

Number (1-year process).

TH16 (Product A + Product B)

Minoxidil 5%

23

TH18 PRODUCT

PATENT AGENT: GOWLING WLG

TH07 - International patent issued

TH07 - Canadian patent issued

TH07 - Chinese patent issued

TH07 - US patent issued

TH07 - European patent issued

TH07 - Macau patent issued

TH07 - India patent issued

TH16 - Canadian patent filed

TH16 - US patent issued

TH16 - European patent filed

TH16 - Hong Kong patent filed

TH16 - Chinese patent filed

24

PROTECTING OUR INTELLECTUAL PROPERTY

Next Steps

1. Build the management and scientific team

2. Recruit board members with strong international pharma network,

M&A and licensing expertise, experience in bringing biotech start-up

companies to unicorn status (>$1 billion), and regulatory and

compliance knowledge

3. Optimize the regulatory process to maximize TH07 Phase 3 trial success

4. Complete the marketing plan and commercialize our TH16 natural

product

5. File with Health Canada to receive NPN for TH16 and DIN for TH18

6. Identify possible pharma partner to develop and market TH07

2525

NEXT STEPS

CONTACT-Jean-Philippe GravelPresident and Chief Executive Officer(514) 804-4569jpgravel@triplehair.ca